- RepliMoney Group (Nasdaq: Reply) announced that the US Food and Drug Administration has accepted a biosimilar license application for RP1 in combination with nivolumab for patients with advanced melanoma.
- The FDA granted BLA priority review to the prescription drug user
Say Job City in Pakistan for today latest jobs opportunities in private and Govt departments. View all new Government careers collected from daily. sayjobcity.com